Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 7/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.38 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | NQO2 | P16083 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10010384 | 0.87 | GNRHR (0.47) | GNRHRBRD4ALDH1A1GFERGAA | |
| SCHEMBL421355 | 0.86 | GNRHR (0.48) | GNRHRBRD4ALDH1A1GFERGAA | |
| SCHEMBL10176988 | 0.86 | GNRHR (0.48) | GNRHRBRD4ALDH1A1GFERSTING1 | |
| SCHEMBL12636229 | 0.79 | HDAC6 (0.45) | GNRHRBRD4GAAAAK1STING1 | |
| SCHEMBL10177017 | 0.78 | NPC1 (0.46) | GNRHRALDH1A1GFERPPARGTP53 | |
| SCHEMBL418842 | 0.78 | ALDH1A1 (0.43) | GNRHRBRD4ALDH1A1GFERGAA | |
| SCHEMBL9968760 | 0.78 | L3MBTL1 (0.41) | GNRHRAAK1STING1PPARGHDAC1 | |
| SCHEMBL10298794 | 0.77 | PPARG (0.50) | PPARGHDAC1TP53THRB | |
| SCHEMBL420597 | 0.77 | GNRHR (0.48) | GNRHRSTING1TP53THRB | |
| SCHEMBL1542762 | 0.75 | BRD4 (0.53) | GNRHRBRD4ALDH1A1GAASTING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172350-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20110065694-A1 | Histamine H3 Inverse Agonists and Antagonists and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2011-03-17 | — | — | US | disclosed |
| WO-2011031818-A2 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011031816-A2 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| US-20110065694-A1 | Histamine H3 Inverse Agonists and Antagonists and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065694-A1 | Histamine H3 Inverse Agonists and Antagonists and Methods of Use Thereof | HRH3, HRH4, HRH2 | GNRHR 500/4885BRD4 519/4885ALDH1A1 2544/4885 |
| US-20120172350-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | HRH3, HRH4, HRH2 | GNRHR 500/4885BRD4 519/4885ALDH1A1 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.